JPM26: Solid Biosciences banks on its AAV capsid to catalyse gene therapy success [Yahoo! Finance]
Solid Biosciences Inc. (SLDB)
Last solid biosciences inc. earnings: 8/14 07:25 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.solidbio.com/investor-relations
Company Research
Source: Yahoo! Finance
Enhanced delivery methods will be key to making gene therapy “really investable again,” said CEO Bo Cumbo at the JP Morgan Healthcare Conference in San Francisco, US, taking place from 12 to 15 January. The clinical-stage genetic medicine company has secured more than 50 agreements, including licences, across industry and academia for use of its proprietary capsid AAV-SLB101, said Cumbo. Investor activity in the cell and gene therapy space has stalled in recent years, with several companies choosing to leave the space in favour of more lucrative modalities. However, the market now appears to be strengthening again and is expected to reach $63bn by 2031, according to a report by GlobalData GlobalData is the parent company of Pharmaceutical Technology. The AAV-SLB101 capsid is designed to bind endocrine receptors on skeletal and cardiac muscle, while reducing liver biodistribution to address associated toxicities. The main downside of AAV vectors used in currently approved ther
Show less
Read more
Impact Snapshot
Event Time:
SLDB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SLDB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SLDB alerts
High impacting Solid Biosciences Inc. news events
Weekly update
A roundup of the hottest topics
SLDB
News
- Solid Biosciences (NASDAQ:SLDB) had its "buy" rating reaffirmed by analysts at Needham & Company LLC. They now have a $16.00 price target on the stock.MarketBeat
- Solid Biosciences Provides 2026 Outlook Underscoring Neuromuscular and Cardiac Pipeline Momentum and Expanded Access to Next-Generation Capsid AAV-SLB101 [Yahoo! Finance]Yahoo! Finance
- Solid Biosciences Provides 2026 Outlook Underscoring Neuromuscular and Cardiac Pipeline Momentum and Expanded Access to Next-Generation Capsid AAV-SLB101GlobeNewswire
- Solid Biosciences Receives FDA Orphan Drug Designation for SGT-212 Dual-Route Gene Therapy for the Treatment of Friedreich’s AtaxiaGlobeNewswire
- Solid Biosciences Doses First Participant in First-in-Class Phase 1b FALCON Trial Evaluating SGT-212 Dual-Route Gene Therapy for the Treatment of Friedreich's Ataxia [Yahoo! Finance]Yahoo! Finance
SLDB
Earnings
- 11/3/25 - Miss
SLDB
Sec Filings
- 1/13/26 - Form 4
- 1/13/26 - Form 144
- 1/7/26 - Form 4
- SLDB's page on the SEC website